In Vienna, Enterprise Imaging offers the “Clinician-First” approach to keeping radiologists in their flow, spotlighting the human behind the innovation…
Browsing: BioTech
Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies…
Everest Medicines (HKG: 1952) today unveiled its 2030 strategy. Following the announcement, the Company’s shares strengthened during the trading session…
Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (Everest Medicines China), has…
Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market…
Enterprise platform, queried through natural language, to help pharma, biotech, and investors make better decisions. High-quality biological patient data, enriched…
AGFA HealthCare has been recognized by KLAS Research for significant satisfaction gains. Customer satisfaction with AGFA’s Enterprise Imaging VNA and…
Kangji Medical Holdings Limited (Kangji Medical or the Company, HKG: 9997) and Knight Bidco Limited (the Offeror) today announced that…
Everest Medicines (HKG:1952) today announced that it has acquired an exclusive license with Visara, Inc. (Visara), a subsidiary of NovaBridge…
Everest Medicines today announced that the first patient has been enrolled in a global multi-center Phase I clinical trial of…
Hong Kong Department of Health accepts NDA for dorzagliatin, the world’s first approved glucokinase activator (GKA). Builds on China approval…
On August 29, Everest Medicines (HKG: 1952) announced its interim results for the six months ended June 30, 2025. The…
ADC pipeline with multiple products entering key clinical stages Revenue increased by 350% year-on-year Focusing on the field of tumor…
In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies,…
– Sales of Innovative Products Up by 27.2% Year-on-Year to RMB7.8 Billion – Profit Attributable to Owners of the Parent…
Everest Medicines today announced that etrasimod (VELSIPITY(R)) has been included in the ACG Clinical Guideline Update: Ulcerative Colitis in Adults…
Everest Medicines (HKG: 1952.HK, Everest) today announced that the Taiwan Food and Drug Administration (TFDA) has officially accepted the New…
Essex Bio-Technology Limited (Essex or the Group, HKG: 1061) is pleased to announce that a Biologics License Application (BLA) for…
Kangji Medical Holdings Limited and Knight Bidco Limited today jointly announced the pre-conditional proposal for the privatisation of Kangji Medical…
Everest Medicines (HKG: 1952) recently announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON(R).…